Abingworth, MVM lead $40m Wilson round

The two lead investors are new backers of the company and were joined in the funding round by historic investor HealthCap. HealthCap provided financial support for the establishment of Wilson in 2012.

The substantial capital injection will support the clinical development of WTX101, which is a de-coppering agent being developed as a treatment for Wilson's disease.

Company
Founded in 2012, Wilson is headquartered in Stockholm with a US office located in Urbana, Illinois.

The company is developing new therapies for the treatment of Wilson's disease, a rare genetic disorder that prevents the body from regulating copper, therefore causing an overload of copper in the liver, brain and other tissues. It can lead to serious liver and brain damage and is fatal if left undiagnosed or untreated.

According to Wilson, the disease affects one in every 15,000 people worldwide.

People
Jonas Hansson is the CEO of Wilson. MVM partner Bali Muralidhar and Abingworth partner Genghis Lloyd-Harris are joining HealthCap managing partner Björn Odlander and partners Mårten Steen and Jacob Gunterberg on the company's board of directors.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Nordics
• Healthcare
• Sweden
• Abingworth Management